ArticleMedecine tropicale et sante internationale2026
[Patterns of resistance to anti-tuberculosis drugs among patients with rifampicin-resistant pulmonary tuberculosis in Yaoundé, Cameroon].
Article in Medecine tropicale et sante internationale, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Screening for multidrug-resistant pulmonary tuberculosis (MDR-PTB) by using the Xpert MTB/ RIF test to detect rifampicin resistance as a surrogate marker for this form of tuberculosis may lead to suboptimal treatment if resistance to other drugs in the treatment regimen is not also determined. The objective of this study was to analyze the patterns of drug resistance to anti-tuberculosis drugs in patients with rifampicin-resistant pulmonary tuberculosis (RR-PTB) who were treated with the standardized 9-11-month regimen in Yaoundé, Cameroon. Materials and methods: This retrospective, cross-sectional study examined the results of anti-tuberculosis drug susceptibility tests in RR-PTB patients who received the standardized 9-11-month treatment regimen at the specialized MDR-PTB treatment center of the Jamot Hospital in Yaoundé from 2013 to 2022. Results: A total of 322 RR-PTB patients were included in the study. Of these, 281 (87.3%) were resistant to at least one of the tested drugs. The pattern of resistance was 43.2% for one drug, 41.6% for two drugs, and 2.5% for three or more drugs. Resistance to isoniazid was the most common (87.3%), followed by ethambutol (42.2%), fluoroquinolones (3.4%), and amikacin (1.9%). Discussion – Conclusion: The majority of RR-PTB patients in Yaoundé had MDR-PTB, and pre-extensively drug-resistant TB was rare. However, the GeneXpert-based strategy for identifying drug-resistant cases (which detects only rifampicin resistance) could lead to the initiation of suboptimal treatment for a non-negligible proportion of patients in our setting. This could result in the amplification of resistance and the transmission of increasingly resistant strains within the community. We recommend that the National Tuberculosis Control Program (NTCP) of Cameroon should adopt and rapidly roll out the new short-course treatment regimen recommended by the World Health Organization given the lack of rapid tests in our country capable of detecting resistance to the various drugs used in the standard 9-11-month regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.